On September 20th, 2017 Edesa Biotech Inc. completed a $7 million financing through a private placement of Preferred Shares. The financing was completed with Lumira Capital, Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices. Edesa Biotech Inc. designs innovative treatments for dermatological and anorectal diseases as well as develops late-stage prescription drugs.
Fasken Martineau advised Edesa Biotech Inc with a team led by Wojtek Baraniak (corporate finance), Christelle Gedeon (intellectual property and regulatory), Kevin Yip (tax), Ryan Mapa (corporate/commercial), Luisa Ferron and Kelly Rowan (corporate), and Zach Austin (articling student).
